CG Oncology, Inc. (CGON) Price & Analysis

Compare

246 Followers

CGON Stock Chart & Stats

$38.00

-$0.55(-1.77%)

At close: Jan 08 4:00 PM EST

$38.00

-$0.55(-1.77%)

Day’s Range― - ―

52-Week Range$14.80 - $46.01

Previous Close$30.46

Volume740.02K

Average Volume (3M)809.82K

Market Cap

$3.01B

Enterprise Value$2.42B

Total Cash (Recent Filing)$680.26M

Total Debt (Recent Filing)$7.24M

Price to Earnings (P/E)―

Beta1.74

Next Earnings

Mar 27, 2026

EPS Estimate

-0.6

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.57

Shares Outstanding80,666,176

10 Day Avg. Volume743,855

30 Day Avg. Volume809,824

Financial Highlights & Ratios

PEG Ratio-0.53

Price to Book (P/B)2.44

Price to Sales (P/S)1573.67

P/FCF Ratio-22.70

Enterprise Value/Market Cap0.80

Enterprise Value/Revenue1.11K

Enterprise Value/Gross Profit5.48K

Enterprise Value/Ebitda-14.66

Forecast

1Y Price Target

$69.64

Price Target Upside83.26% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-2.18

Revenue Forecast (FY)$2.77M

Bulls Say, Bears Say

Bulls Say

Competitive AdvantageThe high price tag of J&J's Inlexzo gives CGON's cretostimogene a clear pricing advantage.

Drug Efficacy And SafetyTreatment with creto led to superior event-free survival in high-risk, BCG-Unresponsive, papillary disease only NMIBC than the approved drugs.

Market PenetrationCGON's cretostimogene is likely to be rapidly adopted and could penetrate as much as 50% of the BCG-unresponsive market.

Bears Say

Investor SentimentShort interest is notably high at 20.2% of the float.

Market SkepticismShort interest is 20.2% of the float, indicating a significant portion of investors are betting against the stock.

Potential VolatilityShort interest is high at 27.5% of the float, which may indicate investor skepticism or potential volatility.

CG Oncology, Inc. News

CG Oncology initiated with an Outperform at Wedbush

Wedbush initiated coverage of CG Oncology (CGON) with an Outperform rating and $70 price target The firm notes...

9d ago

CGON

CG Oncology announces data from BOND-003 Cohort P, CORE-008 Cohort A

CG Oncology (CGON) announced topline data from BOND-003 Cohort P and first results from CORE-008 Cohort A which...

15d ago

CGON

These 3 Stocks Have Strong Upside Potential, Say Five-Star Analysts – 11/27/2025

If you’re looking for investment ideas right now, several top-rated Wall Street analysts (each with five-star ratings) believe...

22d ago

BTDR

CGON

CG Oncology appoints Rossi to its Board of Directors

CG Oncology (CGON) announced the appointment of Christina Rossi to its Board of Directors. Additionally, Simone Song, Senior...

24d ago

CGON

CG Oncology initiated with a Buy at Truist

Truist analyst Gregory Renza initiated coverage of CG Oncology (CGON) with a Buy rating and $62 price target...

26d ago

CGON

Promising Data on CG Oncology’s Cretostimogene Justifies Buy Rating

JonesTrading analyst Soumit Roy has reiterated their bullish stance on CGON stock, giving a Buy rating yesterday. Soumit...

11d ago

CGON

Promising Prospects for CG Oncology, Inc.: Buy Rating Backed by Cretostimogene’s Potential in NMIBC Market

Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on CG Oncology, Inc.. The...

12d ago

CGON

Promising Developments in CG Oncology’s NMIBC Treatment Drive Buy Recommendation

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. and keeping the price...

24d ago

CGON

CG Oncology Appoints Christina Rossi to Board

CG Oncology, Inc. ( ($CGON) ) has shared an announcement. On November 22, 2025, CG Oncology, Inc. announced...

24d ago

CGON

CG Oncology price target raised to $61 from $53 at RBC Capital

RBC Capital raised the firm’s price target on CG Oncology (CGON) to $61 from $53 and keeps an...

1M ago

CGON

CG Oncology, Inc.: Promising Future with Creto’s Accelerated Approval Path and Market Differentiation

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on CGON stock, giving a Buy rating...

1M ago

CGON

Strategic Advancements and Risk Mitigation Drive Buy Rating for CG Oncology, Inc.

CG Oncology, Inc., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sean Laaman...

1M ago

CGON

CG Oncology Advances Bladder Cancer Therapy Development

CG Oncology, Inc. ( ($CGON) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

CGON

CG Oncology Appoints Jim DeTore as Interim CFO

An announcement from CG Oncology, Inc. ( ($CGON) ) is now available. On November 10, 2025, Robert Lapetina...

1M ago

CGON

CGON FAQ

What was CG Oncology, Inc.’s price range in the past 12 months?

CG Oncology, Inc. lowest stock price was $14.80 and its highest was $46.01 in the past 12 months.

What is CG Oncology, Inc.’s market cap?

CG Oncology, Inc.’s market cap is $3.01B.

When is CG Oncology, Inc.’s upcoming earnings report date?

CG Oncology, Inc.’s upcoming earnings report date is Mar 27, 2026 which is in 97 days.

How were CG Oncology, Inc.’s earnings last quarter?

CG Oncology, Inc. released its earnings results on Nov 14, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.559 by -$0.011.

Is CG Oncology, Inc. overvalued?

According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CG Oncology, Inc. pay dividends?

CG Oncology, Inc. does not currently pay dividends.

What is CG Oncology, Inc.’s EPS estimate?

CG Oncology, Inc.’s EPS estimate is -0.6.

How many shares outstanding does CG Oncology, Inc. have?

CG Oncology, Inc. has 80,666,176 shares outstanding.

What happened to CG Oncology, Inc.’s price movement after its last earnings report?

CG Oncology, Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.559. Following the earnings report the stock price went up 8.607%.

Which hedge fund is a major shareholder of CG Oncology, Inc.?

Currently, no hedge funds are holding shares in CGON

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CG Oncology, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-24.74%

Trailing 12-Months

Asset Growth

32.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CG Oncology, Inc.

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology, Inc. (CGON) Earnings & Revenues

Historic Earnings Reports

CGON Stock 12 Month Forecast

Average Price Target

$69.64

▲(83.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","56":"$56","91":"$91","38.5":"$38.5","73.5":"$73.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,38.5,56,73.5,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.25,46.84615384615385,50.44230769230769,54.03846153846154,57.63461538461539,61.230769230769226,64.82692307692308,68.42307692307692,72.01923076923077,75.61538461538461,79.21153846153845,82.8076923076923,86.40384615384616,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.25,45.28,47.31,49.34,51.370000000000005,53.400000000000006,55.43,57.46,59.49,61.52,63.550000000000004,65.58,67.61,{"y":69.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.25,44.15384615384615,45.05769230769231,45.96153846153846,46.86538461538461,47.76923076923077,48.67307692307692,49.57692307692308,50.48076923076923,51.38461538461539,52.28846153846154,53.19230769230769,54.09615384615385,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >